DESyne X2

DESyne X2 Novolimus Eluting Coronary Stent System

The DESyne® X2 Novolimus Eluting Coronary Stent System is a low-profile DES with high flexibility and exceptional deliverability. The ultra-thin design of its stent and polymer coating, with no primer coating, results in one of the thinnest coated struts available.

Hover over the icons to learn more about DESyne X2 design.

DESyne X2

Superior Clinical Results at 5 Years11

EXCELLA II Randomized Controlled Trial

Study Design

  • 21 sites
  • 210 patients randomized 2:1 DESyne DES vs. Endeavor DES
    (Europe, New Zealand, Australia)

At five-year follow-up, the incidence of device- and patient-oriented events was significantly lower in the Novolimus stent (DESyne) group.

EXCELLA II 5 year outcomes published in Eurointervention, December 2016

Reduction in Device-Oriented Composite Endpoints at 5 years

reduction in target lesion revascularization at 5 years

DESyne X2

Cardiac death, MI not clearly attributable to non-intervention vessels, clinically indicated TLR.

DESyne X2
Elixir-Medical-Corporation-Coronary-Device

Corporate Headquarters
920 N. McCarthy Blvd
Milpitas, CA 95035 U.S.
+1.408.636.2000
info@elixirmedical.com

Elixir, Innovation for Life and DESyne are registered trademarks, and DynamX a trademark, in the US and internationally for Elixir Medical Corporation.
DynamX Coronary Bioadaptor System and DESyne X2 Novolimus Eluting Coronary Stent System are CE Mark approved.
©2020 Elixir Medical. All rights reserved.
International (OUS) Use Only. DynamX and DESyne X2 are intended to improve coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Sign up to receive news and information about Elixir Medical, our products and other relevant information as it becomes available.